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Abstract
IMPORTANCE Recent conceptualizations in Research Domain Criteria have indicated that
anhedonia, 1 of 2 core symptoms of depression, which can be treatment resistant, is associated with
deficits in the positive valence system, and inaudible high-frequency sound therapy has been shown
to enhance reward-related brain circuitry. Hence, cognitive behavioral therapy focusing on the
positive valence system enhanced with sound therapy could have a synergistic effect on anhedonia.
OBJECTIVE To test the augmentation effect of inaudible high-frequency sounds on the efficacy of
positive valence system–focused cognitive behavioral therapy to treat anhedonia.
DESIGN, SETTING, AND PARTICIPANTS In this individual-level allocation, exploratory, single-
center randomized superiority pilot trial, patients, therapists, and evaluators will be masked to
intervention or placebo assignment. The trial will take place at a national psychiatric referral hospital
in Tokyo, Japan, among 44 adult patients with clinically significant anhedonia and moderate to
severe depression. Outcomes will be analyzed following the intent-to-treat principle using a
repeated-measures mixed model.
INTERVENTION The intervention group will participate in 8 weekly sessions of positive valence
system–focused cognitive behavioral therapy with in-session exposure to an inaudible high-
frequency sound; the comparison group will undergo cognitive behavioral therapy with in-session
exposure to a placebo sound.
MAIN OUTCOMES AND MEASURES The primary outcome is anhedonia assessed using the self-
reported Snaith-Hamilton Pleasure Scale. The secondary outcome is anhedonia assessed using the
clinician-administered version of the Snaith-Hamilton Pleasure Scale.
DISCUSSION Recruitment for this study began in May 2018, and the projected date of final
allocation is January 2020. A total of 21 eligible patients were registered for participation as of May
30, 2019. To date, treatments for depression do not guarantee clinically successful outcomes. This
pilot trial will provide preliminary evidence of the augmentation effect of high-frequency inaudible
sounds on cognitive behavioral therapy for anhedonia. Overall, exposure to an inaudible high-
frequency sounds does not require attentional or cognitive effort from either patients or therapists;
therefore, results from a future confirmative trial could indicate that cognitive behavioral therapy can
be augmented in an effortless manner.
(continued)
Key Points
Question Can inaudible high-frequency
sounds augment the efficacy of
cognitive behavioral therapy for
anhedonia?
Findings This trial protocol describes a
placebo-controlled, randomized clinical
pilot study testing the augmentation
effect of inaudible high-frequency
sounds on positive valence system–
focused cognitive behavioral therapy
among patients with clinically significant
anhedonia and depression. The sound
presentation system is designed to
optimize exposure to inaudible high-
frequency sounds during face-to-face
cognitive behavioral therapy sessions.
Meaning The preliminary results of this
pilot study could contribute to the
design of confirmatory randomized
clinical trials that will examine the
augmentation effect of inaudible high-
frequency sounds on the treatment of
anhedonia.
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Introduction
Mental disorders cause devastating effects at both the individual and societal level. Among these
disorders, major depressive disorder is the leading cause of the global disease burden.1 According to
treatment guidelines and systematic reviews, cognitive behavioral therapy (CBT) is recommended
for patients with depression who experience moderate to severe symptoms.2 Nevertheless, the
therapies available to treat depression can be improved. A 2010 meta-analysis3 showed that the
standardized mean effect size of CBT for depression was low (d = 0.22) in a high-quality randomized
clinical trial. A 2008 meta-analysis4 reported that 50% of patients relapsed after completing CBT,
and 50% of those who did respond to treatment relapsed within 2 years. To overcome these
situations, translational research bridging neuroscience and CBT has focused on developing novel
CBT approaches or techniques that augment traditional CBT.5-7 Among them, we focused on the
following 2 noninvasive interventions: (1) positive valence system–focused CBT (PoCot) and (2)
inaudible high-frequency sounds. These interventions target the common neurological
underpinnings of anhedonia.
Anhedonia, 1 of 2 cardinal depression symptoms, is known to be less responsive to both CBT
and pharmacotherapy than other depressive symptoms.8,9 Anhedonia is the loss of interest or
pleasure associated with deficits in reward-related brain circuity.10-12 Dysfunction of this circuity
includes blunted activation of the striatal regions and orbitofrontal cortex as well as blunted
mesolimbic dopamine pathways.11,13 It has been suggested that major depressive disorder is
characterized by an underestimation of reinforcements received, a reduced expectation of future
rewards, less frequent endorsement and recall of positive traits in self-referential tasks, a diminished
ability to modulate behavior as a function of reinforcement history, a reduced willingness to make
efforts to gain rewards, and an inability to couple the hedonic impact of stimuli and reward
assumption.13 According to Research Domain Criteria,14 anhedonia reflects disturbances of the
positive valence system.15,16
The positive valence system has been largely neglected in traditional psychotherapeutic
techniques, including CBT.17 Findings in the field of neuroscience have led to the development of a
CBT approach that directly targets the positive valence system; studies have demonstrated the
efficacy of this novel CBT approach.18-21 It requires patients with depression to engage in activities
that are designed to enhance the subconstructs of positive valence systems (eg, behavioral
activation for improving motivation, positive awareness training for improving sensitivity to
rewarding stimuli, and savoring training for the loss of pleasure). Craske et al22 reported that this
positive affect training was more effective for improving anhedonia (ie, increasing positive affect)
and reducing a patient’s negative affect and suicidality than more conventional types of CBT (ie, CBT
approaches targeting negative affect). Therefore, we believe that the PoCot approach may improve
the efficacy of traditional CBT approaches for anhedonia.
The second approach that targets the positive valence system focuses on the hypersonic effect
of inaudible high-frequency sounds. Hypersonic effect refers to the whole-body response following
exposure to inaudible high-frequency sounds via deep brain activity activation, including reward-
related neural circuitry.23 Using inaudible high-frequency sounds recorded in a tropical rain forest,
our research group previously demonstrated this phenomenon using various noninvasive brain
function imaging and physiological measures.23 For example, our positron emission tomography
study23 with healthy control participants demonstrated that inaudible high-frequency sounds,
compared with high-cut placebo sounds, increased blood flow in the reward circuit and affected
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related circuity, including monoaminergic projections distributed across the brain stem, thalamus,
and prefrontal region.
Inaudible high-frequency sounds have also been shown to produce higher
electroencephalographic (EEG) alpha-band (ie, 8-13 Hz) power.23 In addition, in a 2013 study with
healthy controls,24 simultaneous EEG and functional magnetic resonance image acquisitions
indicated that the slow fluctuation component of EEG alpha power was positively associated with
blood oxygen level–dependent signal changes in the brain stem, medial thalamus, and anterior
cingulate cortex, all of which can be considered part of the reward-related neural circuitry. This
observation again suggested that the changes in EEG alpha power induced by inaudible high-
frequency sounds may correspond to the activation of reward-related circuitry. Moreover, inaudible
high-frequency sounds have been reported to promote approach behavior25; this may reflect
reward-system activation (eg, better subjective mood or choosing higher levels of sound volume).
Overall, inaudible high-frequency sounds have been shown to robustly enhance the subjective
experience of sound quality and comfort and to promote approach behavior. Regarding the
underlying physiological mechanisms, our previous study26 demonstrated that the hypersonic effect
may be induced not through the auditory system but through the body’s surface. Although the
underlying physiological mechanisms remain unclear, the overall accumulated evidence robustly
suggests that inaudible high-frequency sounds enhance the reward system.
We hypothesized that the combination of the PoCot approach and inaudible high-frequency
sounds would have a synergistic effect on anhedonia. Although, to our knowledge, no previous direct
findings support this idea, PoCot is designed to enhance the brain reward circuity,18,20 while
inaudible high-frequency sounds increase blood flow.23 In addition, reward circuity activation via
inaudible high-frequency sounds leads to a relaxed attentional state.27 Considering that CBT is a
learning process28 and positive emotions enhance the learning process,29 it is expected that a
positive emotional state induced by inaudible high-frequency sounds will facilitate the learning
process in CBT. Furthermore, inaudible high-frequency sounds are expected to enhance learning via
EEG alpha-band power activation. The alpha-band frequency range inhibits activity in task-
irrelevant brain regions, enabling effective task-irrelevant disengagement for information
processing.30 In addition, inhibiting task-irrelevant memories coupled with alpha-band activity is
believed to enhance semantic orientation, allowing individuals “to selectively access stored
information that represents the meaning of sensory information and ‘higher order information,’ such
as language, mathematics, and geography.”31(p613) Hence, we expect that inaudible high-frequency




This trial was designed with an individual-level allocation with a 1:1 ratio. It is an exploratory,
randomized clinical superiority phase II trial. Therapists, patients, and evaluators will be masked to
allocation. The trial protocol appears in Supplement 1. This report followed the Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT) reporting guideline.
Study Setting
This study will be conducted at the National Center of Neurology and Psychiatry (NCNP) Hospital in
Tokyo, Japan. Patients who are nonresponsive to primary care in their local clinic or hospital are
commonly referred to the NCNP Hospital. A detailed description of the setting appears elsewhere.32
Eligibility Criteria
The inclusion criteria are as follows: patient (1) has anhedonia symptoms (Snaith-Hamilton Pleasure
Scale [SHAPS] score 20), (2) has mild to severe depressive symptoms (GRID-Hamilton depression
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rating scale score 8),33 and (3) is aged 18 years or older. The exclusion criteria are as follows: patient
has (1) current psychotic disorder, (2) current manic episodes, (3) severe substance use disorder, (4)
serious suicidal ideation, (5) severe or unstable physical disorder or major cognitive deficit, and (6)
other problems that may present serious obstacles regarding CBT. Exclusion criteria, except for items
5 and 6, will be assessed using the Mini-International Neuropsychiatric Interview version 7.0.2.34
Interventions
Positive Valence System–Focused CBT
Both the intervention and control group will participate in PoCot, which will be conducted in a face-
to-face, individualized format. Weekly sessions lasting 50 to 60 minutes will be conducted in a room
with sound equipment. This intervention was developed using CBT advances that focus on the
positive valence system,18-21 positive psychological interventions,35 positive emotion regulation
interventions,36 traditional Japanese psychotherapy that emphasizes positive affect and reward,37,38
and findings from neuroscience and emotion research mentioned in the introduction.29,39 Biological
and theoretical background information and details of the intervention are provided in the
eAppendix and eTable in Supplement 2.
Early PoCot sessions will include psychoeducation that emphasizes the importance of the
positive valence system for anhedonia treatment. The participants will then begin to practice
savoring positive sensations and emotions and attentively monitoring positive events in daily life.
Participants will be asked to identify thoughts that interrupt their mindful acceptance of positive
sensations and emotions and to examine alternative thoughts. In parallel, the participants will be
encouraged to identify their strengths and try to use them in daily life. To help identify strengths,
participants will be asked to identify past positive memories.
The focus of the program will then gradually shift from enhancing the patient’s acceptance of
short-term positive experiences (ie, short-term reward) to engaging longer-term, goal-directed, and
more effortful behavior. Psychoeducation on the temporal discounting of rewards in anhedonia will
be provided. The participants will be asked to identify longer-term goals or values in their lives. These
goals will then be divided into smaller steps, and patients will be encouraged to engage in easier
behaviors. Furthermore, patients will be asked to monitor events they are grateful for in daily life and
to practice receiving and providing compliments to enhance positive interpersonal experiences. In
the final session, participants will review the skills they acquired during the program and discuss how
to maintain a positive lifestyle.
Sound Material and Presentation System for Inaudible High-Frequency and Placebo Sounds
The intervention group will be exposed to inaudible high-frequency sounds during PoCot sessions.
Rainforest sounds, a natural sound source containing the richest amount of high frequencies with a
conspicuously fluctuating structure, were chosen as the sound source for this trial. Sounds
containing inaudible high-frequency components (HFCs), referred to as full-range sounds, were
recorded in the rainforest of Borneo from 2004 to 2009 using a high-speed, 1-bit coding signal
processor in a direct stream digital format at a sampling frequency of 5.6 MHz. The electrical signal
contains a wealth of HFCs (ie, >100 kHz). The sounds include animal and bird calls, insects chirping,
and wind. The track is 47 minutes long and will be presented on repeat.
We selected PoCot without inaudible high-frequency sounds (ie, placebo sounds) as the
comparator because previous studies successfully used placebo sounds as a comparator.23,26 There
was almost no difference in the subjective experience of sound quality between inaudible high-
frequency sounds and the placebo sounds. To generate placebo sounds, the inaudible HFCs were
excluded from the original sound material using a low-pass filter (digital finite impulse response filter;
cutoff frequency, 27 kHz; allowable passband ripple, 0.5 dB; stopband, 28 kHz-150 dB) using the
MATLAB signal processing toolbox (MathWorks, Inc).
The level of audible sounds should not disturb conversations during PoCot, and the preferred
sound level may vary depending on individual participants and therapists. Conversely, the inaudible
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HFCs should be presented equally to all participants in the intervention group. To this end, we
constructed an original sound presentation system whereby the sound source signals recorded in a
digital audio player (MR-2000S; KORG) can be divided into 2 pathways by a splitter with an
independent volume control for each pathway (Behringer MX882; Behringer Music Group)
(Figure 1). Using this presentation system, the fixed level of HFCs can be determined regardless of
the audible low-frequency component level.
As the study will use a short-term intervention, all participants will be asked to participate in all
8 sessions. If participants must cancel a scheduled session, an alternative date will be scheduled
immediately. Participants will be exposed to their assigned audio track during the entire PoCot
session. The sound volume will be set in advance at approximately 55 dB. Participants will sit 2 m
away from 2 fixed speakers and tweeters (eFigure 1 and eFigure 2 in Supplement 2).
Objectives
Primary Objective
The primary objective of this trial is to compare the efficacy of PoCot with in-session exposure to
inaudible high-frequency sounds vs PoCot with in-session exposure to placebo sounds on anhedonia
symptoms. Anhedonia symptoms will be assessed by 44 patients who have been diagnosed with
clinically significant anhedonia symptoms using the SHAPS.40
Secondary Objectives
The key secondary objective is to evaluate the severity of anhedonia symptoms using the clinician-
rated version of the SHAPS (SHAPS-C).41 Additional outcome variables, including depression,
positive emotion, negative emotion, satisfaction with life, and psychological well-being will also be
assessed. In addition, a moderation and mediation analysis will be performed using the following 2
measures, which are relevant to the treatment mechanism: (1) perception of environmental rewards
and (2) effort-based decision-making. Perception of environmental rewards will be assessed by the
Environmental Reward Observation Scale.42 Based on behavioral theory, this brief scale was
developed to subjectively evaluate environmental reward as an important treatment mediator of
traditional and new behavioral activation techniques. Effort-based decision-making will be assessed
using the Effort-Expenditure for Rewards Task.43 Also, the relationship between the treatment
process (eg, homework adherence) and outcomes will be examined.
Participant Timeline
The timeline is depicted in Figure 2. During the study period, all patients will continue treatment
as usual.
Figure 1. Sound Presentation System
Digital audio player Splitter and volume controller 
High-pass filter Amplifier Super-tweeter 




In the higher pathway, full-range sound (FRS) sources, which contain high-frequency
components (HFCs) and low-frequency components (LFCs), are sent to wide-range,
powered speakers (Oohashi Monitor Op. 7; Action Research Co) through a volume
controller. In the lower pathway, HFCs are extracted from the sound source after passing
through an independent volume controller using Butterworth Bessel high-pass filters
(cutoff frequency, 40 kHz, −48 dB per octave) and sent to super-tweeters (PT-R9;
Pioneer Co) through a power amplifier (Cerenate; Fidelix). Audible LFCs and HFCs are
transmitted via the first pathway, while the inaudible HFCs are presented via the
second pathway.
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Sample Size
It is difficult to estimate the necessary sample size because previous studies have not directly tested
our hypothesis. Among the most studied augmentation strategies of CBT is the effect of
D-cycloserine on CBT for anxiety disorders; a meta-analysis44 reported that the standardized effect
size of the augmentation on various outcomes ranged from 0.07 to 0.58. Based on this range, we
conservatively selected a relatively low effect size to assess the augmentation effect of inaudible
high-frequency sounds on CBT efficacy. We set a standardized effect size of 0.2 to 0.3 as the clinically
significant minimum level. To detect the effect size, a sample size of 344 to 786 participants is
needed for the main trial. For this pilot trial, we used the approach that was proposed specifically for
calculating sample size for a randomized clinical pilot trial.45 Using this strategy, 32 to 72 individuals
are needed. Hence, a sample size of 40 is sufficient for this trial. Assuming a 12% dropout rate, we
included a total of 44 patients. Before starting the main pilot trial, we will conduct an external
preliminary trial on 3 patients to examine the trial’s feasibility.
Assignment of Interventions
Allocation
The research coordinator will register the participants using an electronic data capture system (HOPE
eACReSS version 5; Fujitsu). Sequences will be generated by this system before the patients begin
the trial (ie, allocation concealment by central registration). The allocation staff will set the audio
track (inaudible high-frequency sounds vs placebo sounds) in accordance with the generated
sequences. Block randomization without stratification will be used.
Masking
All therapists, patients, evaluators, statisticians, and research coordinators will be masked to the
allocation. Masking will be checked using the modified version of the Independent Evaluator
Knowledge of Outcome46 assessment, which was successfully used in a large-scale clinical trial
involving CBT.47 Using the data, we will calculate the blinding index.48
Data Collection, Management, and Analysis
The Table shows an overall description of the assessment during each visit. Assessment tools include
the SHAPS, the SHAPS-C, the GRID-Hamilton Rating Scale, and the Beck Depression Inventory-II.
Primary Outcome
The SHAPS is a 14-item self-report questionnaire used to assess the presence and severity of
anhedonia.40,49 Each item is answered by different 4-point Likert anchors. Following methods used
in previous studies,50,51 the total score will be used. A higher score implies more severe anhedonia
Figure 2. Study Flow Diagram
Randomization
Referred and informed consent
Baseline assessment
Positive valence system–focused cognitive behavioral
therapy with inaudible high-frequency sound
Assessment at 12 weeks after start of trial
Assessment at 21 weeks after start of trial Assessment at 21 weeks after start of trial
Assessment at 12 weeks after start of trial
Positive valence system–focused cognitive behavioral
therapy with placebo sound
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symptoms, and a total score greater than 20 is interpreted as having anhedonia. Importantly, the
reliability of the Japanese version of the SHAPS has been demonstrated (ie, α = 0.90).49
Key Secondary Outcome Measure
The SHAPS-C offers improved instructions and anchors compared with the original SHAPS.41 Similar
to the SHAPS, the SHAPS-C consists of 14 items on a 4-point Likert scale. The SHAPS-C has been
reported to have sufficient reliability (α = 0.90) and validity (concurrent validity with SHAPS,
r = 0.85; P < .001).41 We translated the English version of the SHAPS-C to Japanese using a rigorous
back translation procedure.52,53
Measures of Eligibility, Other Outcomes, Treatment Mechanisms, and Treatment Processes
The Mini-International Neuropsychiatric Interview34 will be used to assess eligibility. The GRID-
Hamilton depression rating scale,33,54,55 Beck Depression Inventory-II,56 Positive and Negative
Affect Schedule,57 Satisfaction With Life Scale,58 and Psychological Well-being Inventory59 will be
used to evaluate the other outcomes. The Environmental Reward Observation Scale42 and Effort-
Expenditure for Rewards Task43 will be used to assess treatment mechanisms, and the Homework
Compliance Scale60 will be used to assess treatment adherence. Detailed information on these
assessments appears in Supplement 1.
Statistical Analysis
Outcome Analysis | A mixed model for repeated-measures analysis will be conducted to analyze
the primary outcome. The dependent variables in this model will be the participants’ SHAPS scores,
assessed during 8 visits from weeks 1 to 11 (ie, intervention period) and at week 12 (ie,
postintervention period). The fixed effects will be allocation, visit, allocation-by-visit interaction, and





Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 Visit 10 Visit 11 Visit 12 Visit 13
Week NA NA −2 −1 0 1-11 12 21
Diagnosis MINI IE X
Primary outcome,
anhedonia
SHAPS PSR X X X X X X X X X X X
Key secondary
outcome, anhedonia




GRID-HAMD IE X X X
BDI-II PSR X X X X
Secondary outcomes
Emotion PANAS PSR X X X X X X X X X X X
Life satisfaction SWLS PSR X X X X
Well-being PWB PSR X X X X
Treatment mechanisms
Anhedonia EROS PSR X X X X
Anhedonia EEfRT PSR X X X
Safety AE TSR and
EA
X X X X X X X X X X
Adherence HCS TSR X X X X X X X
Blinding IEKNO PSR, TSR,
and EA
X X X
Abbreviations: AE, adverse event; BDI-II, Beck Depression Inventory-II; EEfRT, Effort-
Expenditure for Rewards Task; EROS, Environmental Reward Observation Scale; EA,
evaluator assessment; GRID-HAMD, GRID-Hamilton Depression Rating Scale 17 Item;
HCS, Homework Compliance Scale; IE, interview with evaluator; IEKNO, Independent
Evaluator Knowledge of Outcome; MINI, Mini-International Neuropsychiatric Interview
version 7.0.2; NA, not applicable; PANAS, Positive and Negative Affect Schedule; PSR,
participant self-report; PWB, Psychological Well-being Inventory; SHAPS, Snaith-
Hamilton Pleasure Scale; SHAPS-C, Snaith-Hamilton Pleasure Scale, clinician
administered; SWLS, Satisfaction With Life Scale; TSR, therapist self-report.
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SHAPS score before the intervention (ie, week 0). Covariance will be specified as the unstructured
structure. The treatment effects will be presented as the difference in adjusted means between the
allocations at week 12 (ie, visit 12). The confidence interval will be estimated, and a t test will be
conducted to determine the effects of treatment. The treatment effect at other weeks as well as the
standardized treatment effect will also be analyzed. As a secondary outcome analysis, analysis of
covariance, including baseline measures, will be conducted to test the intervention effects on
SHAPS-C scores at week 12. The mixed model for repeated-measures analysis will be conducted for
the other outcomes. Statistical significance will be set at P < .05, and all tests will be 2-tailed.
Analysis Population and Missing Data | The primary and secondary outcome analyses will be
evaluated using the intent-to-treat principle. Our secondary outcome analysis will use all registered
participants who do not meet the discontinuation criteria, as per the protocol set. The mixed model
for repeated-measures analysis will be used to treat missing data. Details of the statistical analyses,
including interim analysis and stopping guidelines, are described in the statistical analysis plan and
trial protocol (Supplement 1).
Monitoring
Data Monitoring
The primary investigator, in collaboration with the research coordinator and data manager, will
conduct on-site and central monitoring and will report the results to the members of the data and
safety monitoring board. All registered cases will be subjected to central monitoring. On-site
monitoring will be conducted for the first 3 registered cases, then for 3 random, preidentified cases
thereafter.
Adverse Events
Adverse events will be assessed using the Common Terminology Criteria for Adverse Events.61 These
include dry mouth, astriction, dysuria, vision dysregulation, orthostatic hypotension, sleepiness,
fatigue, sleeplessness, anxiety or agitation, depression or anhedonia, lack of appetite, gain or loss of
body weight, loss of sexual desire, palpitations, thrill, diaphoresis, headache, dizziness, and others.
Ethical Approval and Informed Consent
This study has been approved by the NCNP institutional review board. The initial protocol was
approved on November 13, 2017, and the modified version was approved on March 5, 2019. Research
coordinators will explain and obtain written informed consent from participants regarding the
following items: objectives, reasons for enrollment, the methods and time period, potential burdens,
predictable risks and benefits, handling of personal information, means for information storage and
disposal, conflicts of interest, any potential invasiveness, and compensation for research-related
injuries.
Confidentiality
The administrator of the patients’ personal information will manage and store all research-related
printed or electronic records with personal information, with a corresponding table of personal
information and research identification numbers to prevent any information from being divulged,
stolen, or lost. The details are described in Supplement 1.
Discussion
This protocol described the design of our pilot study for testing the augmentation effect of inaudible
high-frequency sounds on positive valence system–focused CBT. To date, treatments for depression
and/or anhedonia do not guarantee clinically successful outcomes. In contrast to the studies of the
augmentation effect of D-cycloserine on CBT for anxiety disorders,44 augmentation studies for CBT
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treatments of depression are limited. Exposure to inaudible high-frequency sounds does not require
attentional or cognitive effort from either the patients or therapists; therefore, results from a future
confirmative trial could indicate that cognitive behavioral therapy can be augmented in an
effortless manner.
Limitations
Our trial design has several limitations. First, this pilot trial aims to evaluate the potential efficacy of
augmenting PoCot with inaudible high-frequency sounds. Because of its preliminary nature, this
study only provides information regarding whether it is appropriate to proceed with a larger,
definitive trial. Since our sample size calculation is specifically designed to obtain this information,
the results of this trial should be cautiously interpreted. Second, considering the limited efficacy of
traditional CBT approaches (eg, behavioral activation) and a promising novel neuroscience-driven
treatment for anhedonia, we developed PoCot. However, the efficacy of this intervention has not
been proven as a stand-alone treatment for anhedonia. Thus, further evidence is needed to test
PoCot as a stand-alone treatment for anhedonia. A factorial design would be among the best
methods to accomplish this because the use of inaudible high-frequency sound also has limited
evidence for its efficacy as a stand-alone treatment for anhedonia. Third, we will not control for
patient medications because this would present a potential recruitment barrier. Fourth, we included
various outcome and process measures to evaluate the intervention from multiple perspectives;
these evaluations should be interpreted as exploratory. Fifth, this trial cannot evaluate or offer
detailed information for the following important aspects of the intervention: optimal doses or timing
of PoCot and inaudible high-frequency sounds, the augmentation effect in each module of PoCot,
specific subgroups that are responsive to PoCot and/or inaudible high-frequency sounds, and the
influence of inaudible-high frequency sounds on several distinct reward processes.
Conclusions
This trial is expected to provide initial findings on the synergistic effect of psychological interventions
that target the positive valence system and use inaudible high-frequency sounds. The combination
of CBT and sound therapy could have a synergistic effect on anhedonia.
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